Calithera Biosciences Stock Cash And Equivalents
| CALADelisted Stock | USD 0.05 0.00 0.00% |
Calithera Biosciences fundamentals help investors to digest information that contributes to Calithera Biosciences' financial success or failures. It also enables traders to predict the movement of Calithera Pink Sheet. The fundamental analysis module provides a way to measure Calithera Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Calithera Biosciences pink sheet.
Calithera |
Calithera Biosciences Company Cash And Equivalents Analysis
Calithera Biosciences' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Calithera Biosciences Cash And Equivalents | 41.79 M |
Most of Calithera Biosciences' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Calithera Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, Calithera Biosciences has 41.79 M in Cash And Equivalents. This is 94.91% lower than that of the Biotechnology sector and 90.65% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 98.45% higher than that of the company.
Calithera Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Calithera Biosciences' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Calithera Biosciences could also be used in its relative valuation, which is a method of valuing Calithera Biosciences by comparing valuation metrics of similar companies.Calithera Biosciences is currently under evaluation in cash and equivalents category among its peers.
Calithera Fundamentals
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.56 | ||||
| Current Valuation | (1.1 M) | ||||
| Shares Outstanding | 4.87 M | ||||
| Shares Owned By Insiders | 1.07 % | ||||
| Shares Owned By Institutions | 26.76 % | ||||
| Number Of Shares Shorted | 417.28 K | ||||
| Price To Earning | (14.08) X | ||||
| Price To Book | 1.86 X | ||||
| Price To Sales | 1.71 X | ||||
| Gross Profit | (42.7 M) | ||||
| EBITDA | (43.77 M) | ||||
| Net Income | (39.65 M) | ||||
| Cash And Equivalents | 41.79 M | ||||
| Cash Per Share | 8.59 X | ||||
| Total Debt | 1.67 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 4.82 X | ||||
| Book Value Per Share | (0.40) X | ||||
| Cash Flow From Operations | (43.61 M) | ||||
| Short Ratio | 0.78 X | ||||
| Earnings Per Share | (1.59) X | ||||
| Price To Earnings To Growth | (0.29) X | ||||
| Target Price | 5.0 | ||||
| Beta | 0.25 | ||||
| Market Capitalization | 341.07 K | ||||
| Total Asset | 28.68 M | ||||
| Retained Earnings | (512.62 M) | ||||
| Working Capital | 19.23 M | ||||
| Current Asset | 72.5 M | ||||
| Current Liabilities | 3.83 M | ||||
| Z Score | -29.14 | ||||
| Net Asset | 28.68 M |
About Calithera Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Calithera Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Calithera Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Calithera Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Calithera Pink Sheet
If you are still planning to invest in Calithera Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Calithera Biosciences' history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |